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 Abstract: Background: Nowadays, ionizing radiations are used for various medical and terroristic aims. 
These purposes involve exposure to ionizing radiations. Hence, people are at risk for acute or late effects. 
Annually, millions of cancer patients undergo radiotherapy during their course of treatment. Also, some 
radiological or nuclear events in recent years pose a threat to people, hence the need for radiation mitiga-
tion strategies. Amifostine, the first FDA approved radioprotector, has shown some toxicities that limit its 
usage and efficiency. Due to these side effects, scientists have researched for other agents with less toxici-
ty for better radioprotection and possible mitigation of the lethal effects of ionizing radiations after an ac-
cidental exposure. Flavonoids have shown promising results for radioprotection and can be administered 
in higher doses with less toxicity. Studies for mitigation of ionizing radiation-induced toxicities have con-
centrated on natural antioxidants. Detoxification of free radicals, management of inflammatory responses 
and attenuation of apoptosis signaling pathways in radiosensitive organs are the main mechanisms for ra-
diation protection and mitigation with flavonoids and natural antioxidants. However, several studies have 
proposed that a combination in the form of some antioxidants may alleviate radiation toxicities more ef-
fectively in comparison to a single form of antioxidants. 
Conclusion: In this review, we focus on recent findings about natural radioprotectors and mitigators 
which are clinically applicable for radiotherapy patients, as well as injured people in possible radia-
tion accidents. 
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1. INTRODUCTION 
For several years, the search for development of a novel 
and more potent radioprotector was one of the interesting 
goals in radiobiology. Low toxicity and cost are important 
properties of an appropriate radioprotector [1]. However, a 
number of developed radioprotectors were avoided in wide  
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clinical applications due to their high toxicities. In the past 
two decades, several experiments have revealed that herbal 
radioprotectors can be used in higher doses with lower toxic-
ities. Amifostine is the first FDA approved radioprotector. 
Despite promising radiation protection properties, it may 
cause severe side effects on patients, resulting in the discon-
tinuation of amifostine treatment [2]. 
In recent years, trends in the development of novel radio-
protectors are drifting towards natural compounds with less 
toxicities [3]. They should have some properties applicable 
in clinical radiotherapy or radiation disaster. However, the 
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characteristics of radioprotectors in these two cases are not 
similar. For example, in radiotherapy, it is very important 
that the administered agent does not cause the protection of 
tumor cells. Both radioprotectors and mitigators should have 
minimal toxicities and protect normal tissues especially radi-
osensitive organs such as hematopoietic and gastrointestinal 
[4]. Although the search for radioprotectors has been on for a 
long time, there has been more emphasis on the development 
of radiation mitigators with high efficiency. The most im-
portant focus in this issue is mitigation of radiosensitive or-
gans such as bone marrow and gastrointestinal system [5]. 
Results of several experiments have shown that cell me-
tabolism and inflammatory responses following exposure to 
radiation play a key role in continuous free radical produc-
tion and disruption of normal organ functions [6-9]. Attenua-
tion of oxidative damage and inflammation following expo-
sure to ionizing radiation can alleviate damage to radiosensi-
tive organs, leading to increased survival [10, 11]. The sup-
pression of reactive oxygen species (ROS) derived mito-
chondria, NADPH oxidase enzymes and COX-2 has shown 
promising results [12-15]. Targeting mitochondrial ROS is 
one of the new strategies that has also shown promising re-
sults. Development of 4-Amino-Tempo is the best example 
of a mitochondrial targeted derivative [16-18]. Selenium, 
Selenium-L-methionine, ascorbic acid etc., are natural agents 
that have proved effective. 
2. MOLECULAR MECHANISMS FOR CONTINUOUS 
ROS PRODUCTION FOLLOWING EXPOSURE TO IR 
A large body of studies has revealed that chronic oxida-
tive injury following exposure to IR plays a key role in radia-
tion toxicity. A study showed that exposure of mice to IR 
lead to ROS production in hematopoietic bone marrow cells 
for 8 weeks. Also, this study showed that upregulation of 
NOX4 and NOX2 is responsible for continuous ROS pro-
duction and genomic instability in bone marrow cells. More-
over, their results showed that inhibition of NOX4 can pro-
tect mice similar to a potent radioprotector (N-acetyl cyste-
ine) [19, 20]. Other studies confirmed that continuous ROS 
production through stimulation of redox interactions plays a 
key role in the development of both early and late effect of 
IR [21-23]. Weyemi et al. showed that inactivation of both 
NOX4 and NOX5 can mitigate ROS production and oxida-
tive DNA damage in irradiated human fibroblast cells [24]. 
In animal model, it has shown that upregulation of pro-
oxidant enzymes such as NOX1, NOX4, COX-2, iNOS and 
also increased superoxide production by mitochondria are 
involved in the development of pneumonitis and fibrosis [25-
27]. Similar results have shown for intestinal cells, vascular 
endothelial cells, mice brain, etc [28-30]. 
Exposure to ionizing radiation cause damages to DNA 
and other organelles. This is associated with cell death 
through some mechanisms such as mitotic catastrophe, apop-
tosis, necrosis, autophagy and senescence [31]. Studies have 
shown that apoptosis to necrosis ratio is higher following 
exposure to doses lower than 1 Gy. However, for doses 
higher than 2 Gy, necrosis is more common. Ingestion of 
apoptotic bodies by macrophages causes secretion of anti-
inflammatory cytokines such as IL-10 and TGF-β [32]. 
However, the release of necrotic products such as oxidized 
DNA and high mobility group box 1 (HMGB1) leads to 
stimulation of lymphocytes to elevate the expression of tran-
scription factors like nuclear factor-κB (NF-κB), signal 
transducer and activator of transcription (STAT), mitogen-
activated protein kinases (MAPKs), Intercellular Adhesion 
Molecule 1 and vascular cell adhesion molecule 1 (VCAM-
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Fig. (1). Mechanisms of radiation toxicity in normal tissues. Ionizing radiation cause generation of ROS and cells death, leading to initiation 
of inflammatory responses and chronic free radical production. These are associated with several side effects in irradiated normal tissues 
such as fibrosis, pneumonitis, dermatitis, ulcer and etc. Suppression of oxidative damage and other factors involved in these side effects by 
various agents such as flavonoids can help the management of radiation toxicity. 
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1) [33]. These transcription factors upregulate the expression 
of inflammatory mediators and pro-oxidant enzymes such as 
cyclooxygenase-2 (COX-2), iNOS and NADPH Oxidase [5, 
34]. These pro-oxidant enzymes produce ROS and then 
stimulate more free radical production by mitochondria via a 
phenomenon known as ROS-induced ROS [35]. Hence, sup-
pression of inflammatory mediators and pro-oxidant en-
zymes as well as mitochondrial ROS can be proposed for 
inhibition of these signaling pathways and more injury fol-
lowing exposure to ionizing radiation [36-39]. Also, it has 
shown that some protective effect of radioprotectors and 
mitigators are mediated through blunt of these pathways 
[40]. (Fig. 1). 
3. RADIATION TOXICITY IN RADIOTHERAPY 
More than half of cancer patients undergo treatment with 
ionizing radiation during their course of treatment. As mil-
lions of patients go through this process each year, manage-
ment of the side effects of this treatment modality has been 
noted in various reports [41]. Although the introduction of 
novel technologies in radiotherapy instruments can help the 
management of radiation toxicity, the risk of damage to 
normal functions of organs remain. These novel technologies 
such as conformal radiotherapy, intensity-modulated radio-
therapy (IMRT), image-guided radiotherapy (IGRT), stereo-
tactic body radiotherapy (SBRT), drug delivery techniques 
and using heavy ion particles facilitate normal tissue sparing 
during the course of treatment [42, 43]. Most of these tech-
niques reduce the volume of irradiated organs, while heavy 
particle radiation reduces the dose to the normal tissue via an 
interesting property named Brag peak [44]. Despite these 
improvements, radiation toxicity remains an unsolved prob-
lem in radiotherapy. The features of radiation toxicity in 
each organ is different from others. In addition, the mecha-
nisms of toxicity and tissue response vary [45]. According to 
published documents, oxidative stress and inflammatory 
responses are responsible for various side effects to the pa-
tients [12]. The most common consequences of exposure to 
clinical doses of ionizing radiation include skin burning, 
mucositis, xerostomia, gastrointestinal bleeding and fibrosis, 
lung pneumonitis and fibrosis, cardiovascular disorders, in-
fertility etc. [46-48]. So far, several experiments have been 
conducted for the amelioration of these side effects. Hence, 
achieving an appropriate protocol for the clinical applica-
tions of radioprotectors requires further studies. 
4. RADIATION DISASTERS; POSSIBLE ROLE OF 
MITIGATORS 
The threats of radiological or nuclear disasters leading to 
exposure of a large number of people to ionizing radiation 
have been felt in this century. After exposure to an acute 
high dose of ionizing radiation, exposed people may suffer 
fatal damages to bone marrow or gastrointestinal organs. 
This is referred to as acute radiation syndrome. Moreover, 
exposure to sub-lethal doses of ionizing radiation results in 
an increased risk of various diseases such as cardiovascular 
and neurophysiological disorders, lung pneumonitis and fi-
brosis, as well as cancer [49-51]. In an accidental radiologi-
cal or nuclear disaster such as a dirty bomb, nuclear explo-
sion, and damage to nuclear plants (like Fukushima and the 
Chernobyl disasters), a large number of people may be af-
fected with a need for medical care. 
Several studies have been conducted to identify potent 
and effective radiation mitigators for the alleviation of acute 
and late effects of ionizing radiation in a possible radiation 
disaster. In studies conducted to ameliorate the dangerous 
effects of radiation, crucial attention must be paid to the 
mechanisms of radiation-induced cell death in bone marrow 
and gastrointestinal as two radiosensitive organs [52, 53]. 
However, some studies attempted to develop mitigators for 
the lung and heart [54-57]. It seems that continuous ROS 
production following exposure to ionizing radiation plays a 
key role in the disruption of these organs. For example, ad-
ministration of some antioxidants after irradiation can help to 
alleviate radiation toxicity in radiosensitive organs and in-
crease survival. However, it may be not true for all organs. 
For example, treatment with ROS scavenging agents follow-
ing irradiation can’t mitigate kidney damage. 
In recent years, some agents have been developed for 
mitigating radiation-induced hematopoietic injury [58, 59]. 
JP4-039 (GS-Nitroxide) has been tested for this aim. It is a 
mitochondria-targeted nitroxide concentrated in the mito-
chondria and scavenges free radicals [60, 61]. A study 
showed that treatment with this agent (10 mg/kg) a day after 
whole body irradiation with 9 Gy can stimulate the recovery 
of hematopoiesis and increase survival rate in mice [62]. In 
addition to mitochondrial targeting, the fact that TGF-β and 
NADPH oxidase are other targets with the ability to cause 
inhibition has been proposed for mitigation of radiation-
induced toxicity in hematopoietic systems [63-65]. 
In a study by Rabender et al. it has been discovered that 
using IPW-5371 (a small molecule TGF-β receptor 1 (TGF-
βR1) inhibitor) a day after thorax irradiation with 11.5 Gy 
can mitigate radiation induced lung and heart fibrosis. Their 
result showed that inhibition of TGF- βR1 for 6 or 20 weeks 
following thoracic irradiation can increase survival rate 
compared to irradiated mice without treatment [66]. In a sim-
ilar study, using small molecule antioxidant (AEOL 10150) 
indicated a 28% increase in survival following administra-
tion for 4 weeks [67]. Using another inhibitor of TGF-βR1 
(LY2109761) 4 weeks after a single irradiation of the thorax 
with 20 Gy showed mitigation of lung inflammation and 
fibrosis [68]. Other studies have shown that targeting of pro-
inflammatory and pro-fibrotic mediators can mitigate severe 
inflammation and fibrosis in the heart and lung, leading to an 
increase in survival [69-73]. 
5. AMIFOSTINE AND KERATINOCYTE GROWTH 
FACTOR (KGF) AS FDA APPROVED RADIOPRO-
TECTORS 
Amifostine, a chemical agent, is the first FDA approved 
radioprotector used for protection against ionizing radiation 
induced xerostomia in head and neck cancer patients [74]. It 
is a thiol compound that neutralizes free radicals and pre-
vents DNA oxidative injury due to the presence of SH group 
in its structure [75]. Clinical studies have shown that amifos-
tine is able to alleviate radiation toxicity in more than half of 
the patients with lung, head and neck, breast or uterus malig-
nancies [76]. In addition to potent radioprotection of parotid 
gland in head and neck cancer patients, it has been reported 
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that amifostine administration does not interfere with thera-
peutic outcomes of radiotherapy or chemo/radiation therapy 
[77]. However, its use is limited as a result of high toxicity 
and little or no radioprotective effect on most organs. The 
high toxicity of this agent may cause discontinuation of its 
use and in some situations delay of radiotherapy. This may 
have an effect on the therapeutic ratio as well as a reduction 
in final efficiency of radiotherapy [78]. Keratinocyte growth 
factor (KGF) is another FDA approved agent that has shown 
radioprotective effect. KGF was proposed for ameliorating 
radiation-induced oral mucositis and salivary hypofunction 
[79, 80]. The radioprotective effect of KGF results from 
stimulating stem cell proliferation, leading to the expansion 
of progenitor and functional cells in irradiated area [81]. Ap-
plication of KGF is limited to mucus cells and has a risk of 
carcinogenesis [82]. 
6. FLAVONOIDS AND NATURAL ANTIOXIDANTS 
Flavonoids have a potent antioxidant effect due to their 
high redox potential, which allows them to act as hydrogen 
donors and reducing agents, metal chelating potential as well 
as quenchers of singlet oxygen [83]. In plants, flavonoids are 
the most abundant type of photochemical, which protect 
them against detrimental effects of ultraviolet rays, patho-
gens, and oxidative stress conditions [84]. A large number of 
studies have proposed regular consumption of flavonoids in 
reducing the risk of some malignancies such as the incidence 
of prostate and breast cancer [85, 86]. Flavonoid intake has 
also been discussed as potentially beneficial in terms of pre-
vention of cardiovascular disorders as well as inflammatory 
diseases [87]. The radioprotective effects of some flavonoids 
are a result of their potent antioxidant and anti-inflammatory 
effects. In addition, it is believed that the radioprotective 
effects of flavonoids are due to the presence of phenolic hy-
droxyl groups in their structures [88]. 
Several studies have been conducted to evaluate the 
possible positive effects of antioxidants for preventing radia-
tion toxicity without a negative effect on tumor control. Some 
studies proposed the use of natural antioxidants such as beta 
carotene and vitamin E for preventing mucositis, melatonin 
for patients with brain cancer and a combination of some an-
tioxidants for prostate cancer patients [89-92]. Studies con-
cluded that with limited exceptions, administration of antiox-
idants does not interfere with tumor control [93]. Among the 
most interesting flavonoids which have been studied in recent 
years include curcumin, hesperidin, resveratrol, quercetin, 
flaxseed, ocimum sanctum, sesamol and rutin. However, 
some natural antioxidants such as selenium, Co-enzyme q10, 
α-tocopherol, cafeic acid and ascorbic acid have shown prom-
ising results. Moreover, some studies proposed that using a 
combinational form of these antioxidants may be more effec-
tive in comparison to a single form [94, 95]. Less toxicity of 
flavonoids and natural antioxidants is an interesting ad-
vantage. Hence, making it a suitable natural medicine for 
individuals who may be exposed to high doses of ionizing 
radiation in radiotherapy or a radiation accident [96]. 
7. CURCUMIN 
Among the various herbal agents, curcumin has been 
studied widely for its radiation protection effects. Turmeric 
(curcuma) is well-known and used for medicinal purposes in 
Indian and Chinese traditional medicine. Curcumin was 
found to be a potent free radical scavenger with abilities to 
inhibit the development of lipid peroxidation and neutralize a 
variety of reactive oxygen and nitrogen species in different 
animal models [97, 98]. In addition to the direct suppression 
effect of curcumin on free radicals, it can inhibit inflamma-
tion via reduction of inflammatory cytokines (such as IL-1a, 
TNF-α) and inflammatory mediators (such as NF-кB and 
Smad) [99]. Its anti-inflammatory effect can help the reduc-
tion of oxidative stress induced by redox activity of inflam-
matory cells [100]. 
One of the most interesting properties of curcumin is that 
despite its beneficial medical features, no amount of toxicity 
has been traced to it. Administering 8 gm/day of curcumin 
for 3 months has shown no problem in voluntary individuals 
[101]. In a recent study on patients with breast cancer, treat-
ment with 6 gm of curcumin during radiotherapy showed 
protection against radiation-induced dermatitis without any 
significant toxicity [102]. In addition to dermatitis, curcumin 
has indicated a protective effect against other side effects of 
radiation such as pneumonitis, fibrosis, mucositis, myelopa-
thy, neural toxicity and others [103-107]. The anti-
inflammatory effect of curcumin has a central role in radio-
protection against these toxicities. Studies conducted to 
evaluate the effects of curcumin on radiation-induced pneu-
monitis revealed that it offers protection by decreasing in-
flammation mediators like NF-κB and its cascades such as 
inflammatory and fibrogenic cytokines [108]. In addition, it 
aids the reduction of gastrointestinal toxicities through pro-
tection of mucosal cells against ROS production and oxida-
tive damage [109, 110]. 
One of the most important advantages of novel radiopro-
tectors that should be noticed is their effects on cancer cells. 
Although various tumors are genetically deferent, anti-
inflammatory effects of some herbal agents may be proposed 
for suppression of angiogenesis and tumor growth. An inter-
esting advantage for curcumin is its anti-cancer effects. This 
advantage makes curcumin a suitable radiosensitizer [111-
113]. 
8. HESPERIDIN 
Hesperidin is a natural bioflavonoid. It was first extracted 
in 1828 by French chemist Lebreton from the spongy inner 
portion of orange peel. This bioflavonoid has been found in 
other citrus fruits. In traditional Chinese medicine, hesperi-
din has been used for inflammation and allergy diseases 
[114]. Nowadays, it is used for the treatment of a wide range 
of disorders such as neurological disorders, cardiovascular 
diseases, and others [115, 116]. Hesperidin has shown radio-
protective abilities for both early and late effects in different 
organs. 
Hosseinimehr et al. [117] evaluated the radioprotective 
effects of hesperidin on radiation-induced bone marrow cells 
damage. They used different doses of hesperidin ranging 
from 10-160 mg/Kg at 45 min prior gamma rays exposure 
with dose 2 Gy. Their results showed that all administered 
doses of hesperidin can reduce DNA damage in bone mar-
row cells and increase proliferation ratio. Further results 
showed that the most effective dose of hesperidin for reduc-
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ing bone marrow DNA damage is 80 mg/kg body weight. No 
toxicity effect was observed at a dose of 80 mg/Kg, while a 
dose of 160 mg/kg showed signs of toxicity. It was con-
firmed that the protective effect of hesperidin could be medi-
ated via inhibition of apoptosis in radiosensitive cells [118]. 
Moreover, hesperidin has the ability to reduce the level of 
inflammatory cytokines such as IL-1β, IL-6, and TNF-α, 
with improved nutritional functions [119]. 
A study by Park et al. [120] indicated that hesperidin has 
the ability to mitigate the hepatocellular cells of Sprague–
Dawley rats against oxidative damage induced by ionizing 
radiation. In this study, rats were irradiated with gamma rays 
in three different doses of 1, 3 and 5 Gy. Afterwards, the rats 
were treated with hesperidin for 7 days after exposure with 
50 mg/kg or 100 mg/kg. The results showed that although 
treatment with 50 mg/kg hesperidin can protect rats against 1 
Gy and 3 Gy, a higher dose of 5Gy will require a higher 
amount of hesperidin. In this study, it was reported that hes-
peridin can ameliorate the serum level of hepatic oxidative 
damage as well as oxidative stress in liver tissue. Oral ad-
ministration of hesperidin before irradiation of mice with a 
dose of 100 mg/kg body weight resulted in amelioration of 
oxidative damage and stimulation of antioxidant enzymes, 
including superoxide dismutase, glutathione (GSH) and glu-
tathione peroxidase (GSPx) in the skin [121]. 
A potent radioprotective and anti-inflammatory effect of 
hesperidin has been seen in heart tissues. Treatment of rats 
with hesperidin before exposure of chest area to a high dose 
of gamma radiation has shown improvement in survival as 
well as reduction of oxidative damage, vascular leakage, in-
flammation, fibrosis and infiltration of macrophages, lym-
phocytes and mast cells [122]. Moreover, treatment with hes-
peridin for 7 consecutive days before irradiation was effective 
in ameliorating serum heart disease markers [123]. These 
results have also been observed for lung tissues [124, 125]. 
The radioprotective effects of hesperidin have been revealed 
for other organs such as testis and kidney [123, 126]. 
9. RESVERATROL 
Another herbal agent that has shown potent radioprotec-
tive effect is resveratrol. Resveratrol (C14H12O3) is a natural 
polyphenolic compound produced by some plants such as 
grapes, peanuts, soy and etc., in response to pathogen agents. 
This herbal product was isolated for the first time in 1940 by 
Japanese scientists. Resveratrol has been observed to reduce 
aging and promotes cell survival by simulating sirtuin-1 
(Sir1) which consequently increases genomic stability [127]. 
Sir1 via upregulation of p53 has a key role for protection 
against genotoxic agents [128]. In addition to immunoregula-
tory and epigenetic effects of resveratrol, a study proposed 
that it can strongly protect cells against toxic effects of free 
radicals [129]. Interesting properties of resveratrol as a po-
tent antioxidant have been observed to possess other various 
health benefits such as radioprotective effect and neuropro-
tective properties [130]. 
Carsten et al. [131] showed that administering resveratrol 
with a daily dose of 100 mg/kg for 3 days before whole-body 
irradiation with 3 Gy single dose of γ-rays reduces the num-
bers of chromosome aberrations in the bone marrow cells of 
mice. Also, this study reported that daily treatment with 
resveratrol at this dose does not lead to genotoxicity. 
Although resveratrol can't scavenge free radicals directly, it 
can upregulate the activity of antioxidants enzymes such as 
SOD and GPX in hematopoietic cells following exposure to 
ionizing radiation [132]. In addition to the antioxidant effects 
of resveratrol, resveratrol can suppress chronic free radical 
production via amelioration of inflammatory responses in the 
bone marrow stem cells of mice. Zhang et al. showed that 
treatment with resveratrol for 7 days before exposure to 7.2 
Gy γ-rays (as a lethal dose of ionizing radiation) ameliorates 
the upregulation of NADPH oxidase 4 (NOX4) and subse-
quent NOX4-derived ROS production, which is involved in 
stem cell apoptosis and senescence. The result indicated an 
increase in survival from 25 to 66 % [133]. 
Resveratrol has also shown the radioprotective effect on 
the chromosome aberrations in peripheral blood lymphocyte 
of mice. In a study designed by Hejazi et al. revealed that 
intraperitoneal injection of resveratrol in 50 and 100 mg/kg 
body weight 2 hours before whole body irradiation (2Gy) 
resulted in a significant reduction in DNA damage. Admin-
istration of injected resveratrol doses did not show any tox-
icity [134]. 
Resveratrol can protect against the detrimental effects of 
ionizing radiation in the intestinal organ. It can ameliorate 
oxidative stress, DNA damage, apoptosis and subsequent 
consequences following exposure to gamma radiation in 
mice intestinal tissue. These radioprotective effects are me-
diated by acetylation of p53 and activation of Sir1, resulting 
in resistance of intestinal crypt cells to apoptosis [135]. Ad-
ministering resveratrol before irradiation of rats’ abdomen 
with 10 Gy could ameliorate increased level of inflammatory 
cytokine, regulatory T cells, and oxidative DNA damage, 
whereas it increased the white blood cell counts such as 
CD4+ T cells [136]. These results have also confirmed the 
long-term inflammatory effects of radiation [137]. 
10. QUERCETIN 
Quercetin belongs to the flavonoid compounds, which are 
found in aerial photosynthetic plants like onions, kale, apples, 
French beans and others [138]. Quercetin has shown some 
cancer chemotherapeutic and chemopreventative properties 
[139]. Some studies proposed that quercetin protects normal 
cells via scavenging of free radicals, inhibition of lipoprotein 
oxidation, and inhibition of eicosanoid synthesis [140, 141]. 
Despite the beneficial effects of quercetin, some studies re-
ported mutagenesis and carcinogenesis effects [142]. 
Quercetin has radioprotective properties in some organs. 
Benkovic et al. evaluated the protective effect of quercetin 
against ionizing radiation induced DNA damage in mice 
leukocytes. In this study, the radioprotective effect as well as 
the cytotoxicity of quercetin was evaluated using the comet 
assay. Quercetin was administered with a dose of 100 mg/kg 
body weight for 3 consecutive days before and after irradia-
tion with 9 Gy. Results showed no toxicity for quercetin on 
leukocyte counts. Also, treatment with quercetin could sig-
nificantly protect mice leukocytes against DNA damage 
[143, 144]. Devipriya et al. examined the radioprotective 
effect of quercetin in human peripheral blood lymphocytes. 
In this study, authors observed its ability to protect cells 
from the genotoxic effects of ionizing radiation in a dose-
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dependent manner. Also, they found that the most protective 
effect can be achieved with a concentration of 24 µM. More-
over, quercetin could improve the depletion of antioxidant 
enzymes and non-enzymes [145]. Stimulation of antioxidant 
enzymes by quercetin have also been revealed in red blood 
cells [146]. In addition to direct and indirect antioxidant ef-
fects of quercetin, some experiments showed its capability to 
manage deleterious effects of ionizing radiation by suppress-
ing inflammatory pathways. In an animal study, quercetin 
showed the ability to blunt mitogen-activated protein kinases 
(MAPKs) pathway genes such as JNK, p38 and p44/p42, as 
well as inhibiting NF-κB by preventing its nuclear transloca-
tion and degradation of IκB-α [147]. In addition to these, 
quercetin can reduce the release of inflammatory cytokines 
[148]. 
11. OCIMUM SANCTUM 
Ocimum sanctum is an Indian holy basil and water-
soluble flavonoid with promising effects on preventing radia-
tion toxicity. It can scavenge different types of free radicals 
such as superoxide anion radical, NO, hydroxyl radical etc 
[149]. Adhvaryu et al. showed that treatment with ocimum 
sanctum before irradiation with 2 Gy of gamma rays can 
mitigate genotoxicity induced by ionizing radiation in bone 
marrow cells of mice. Their results showed that the protec-
tive effect of ocimum sanctum is less than curcumin [150]. 
In addition to the direct effects of ocimum sanctum on free 
radicals, its administration (10 mg/kg for 5 days) can stimu-
late antioxidant enzymes to reduce the toxicity of radiation 
on normal tissues [151]. Evaluating the possible effects of 
ocimum sanctum on melanoma and fibrosarcoma bearing 
mice showed that it does not cause radioresistance of these 
tumor cells [152]. This may be of help in the clinical applica-
tions of this agent for radiotherapy patients. However, this 
result needs verification in clinical trial studies. 
12. RUTIN 
Rutin is a flavonoid present in citrus fruits that acts as 
ROS scavenger as well as a chelator for metals prone to act 
as pro-oxidants. In addition, evidence showed that rutin had 
beneficial properties such as its anti-inflammatory and anti-
cancer effects, as well as neuroprotective and cardioprotec-
tive effects [153, 154]. In in vitro studies, rutin showed an 
amelioration effect on DNA damage and mutation, as well as 
an increase in cell survival [155, 156]. Its radioprotective 
effect was also investigated in in vivo studies [157-159]. The 
presence of a phenolic group was suggested to be responsible 
for this effect [157]. Also, studies indicated that rutin stimu-
lates the production of antioxidant peptides and enzymes 
including SOD, GSH, glutathione-S-transferase (GST) and 
catalase [159]. Treatment with 50 mg/kg before irradiation 
with 4 Gy significantly ameliorated the toxic effects of ioniz-
ing radiation on bone marrow cells of mice, while a lower 
dose of 25 mg/kg has a slight effect [160]. Further studies 
are necessary to explain the mechanisms and possible radio-
protective effects of rutin in different organs. 
13. SESAMOL 
Sesamol has been purified from sesamolin. It is com-
posed of phenolic and benzodioxole group in its structure. In 
addition to the antioxidant effect of phenolic, benzodioxole 
scavenges hydroxyl radicals. In several in vitro and in vivo 
studies, the various beneficial effects of sesamol such as an-
tioxidant, anti-inflammatory and anti-microbial properties 
have been reported [161]. Sesamol can inhibit enzymes in-
volved in the metabolism of fatty acids and prostaglandins, 
which are involved in inflammation and oxidative damages 
[162, 163]. The radioprotective effects of sesamol have been 
investigated in some studies. 
In an in vitro study with V79 cells, Mishra et al. [164] 
identified the potent antioxidant and radioprotective effects 
of sesamol. Interestingly, their investigation revealed the free 
radical scavenging capacity of sesamol to be 20 times higher 
than melatonin. An in vivo study on bone marrow cells of 
mice has shown the similarity between sesamol and amifos-
tine as regards their radioprotective effects on this organ. 
This study showed that injecting 20 mg/kg of sesamol 30 
minutes before exposure to 2 Gy gamma rays resulted in a 
significant reduction of DNA damage markers including γ-
H2AX and micronuclei formation. This study indicated that 
sesamol is a potent radioprotector agent against genotoxic 
effects of radiation with similarities to amifostine, although 
its toxicity is more tolerable [165]. This result was confirmed 
by Khan and colleagues [166]. They showed that administer-
ing 100 or 50 mg/kg of sesamol, 30 minutes before irradia-
tion with 7.5 Gy resulted in a remarkable increase in survival 
of mice. Their results showed a significant decrease in apop-
tosis of bone marrow cells and gastrointestinal organ, as well 
as regenerating crypt cells. The protective effects of sesamol 
were more obvious for higher doses [166]. 
Parihar et al. evaluated the radioprotective effects of dif-
ferent drug doses of sesamol in albino mice. They adminis-
tered sesamol in 10 to 100 mg/kg body weight before irradia-
tion with 9.5 Gy. Their results showed that administering 50 
mg/kg had a maximum effect on survival, while higher doses 
gave the best result for the mitotic index of bone marrow 
cells. In addition, treatment with sesamol in all doses could 
increase antioxidant capacity through activation of GSH, 
catalase and total thiols [167]. 
14. CAFFEIC ACID 
Caffeic acid is a phenolic compound whose molecular 
formula is C9H8O4. This compound is a natural antioxidant 
with potent anti-inflammatory and antimicrobial properties 
[168]. Various studies have revealed its inhibitory effect on 
cancer cell proliferation by modulating oxidative mecha-
nisms [169-171]. However, the toxicity of caffeic acid on 
normal human tissues remains a subject of debate. Chen et 
al. [172] examined the protective effects of caffeic acid on 
radiation-induced pneumonitis. They showed that adminis-
tering caffeic acid (30 mg/kg/day for 3 days) has no cytotox-
icity in mice lung tissues. Furthermore, their results showed 
that it alleviates pneumonitis via amelioration of increased 
level of inflammatory mediators and cytokines such as NF-
κB, iNOS and TNF-α after an exposure to radiation (10 Gy 
or 20 Gy). Caffeic acid was administered 30 minutes before 
exposure then 10 days after. It has the ability to increase the 
activities of antioxidant enzymes and glutathione [173]. 
These properties can help reduce ROS and nitric oxide, in-
ducible nitric oxide synthase, and other detrimental effects of 
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ionizing radiation such as damage to vascular endothelial 
cells. 
15. MELATONIN 
Melatonin was first discovered in the pineal hormone in 
1953 by Aaron B. Lerner, but its antioxidant effect was 
found 40 years later. It can be found in numerous plants such 
as tomatoes, olive oil, ginger, walnuts, pineapple, cereals, 
germinated legumes and others [174]. Melatonin has various 
properties such as antioxidant, anti-inflammatory as well as 
neuroprotective effects [175]. Its dietary administration is 
associated with an increase in melatonin levels of serum and 
tissues. Melatonin can scavenge free radicals directly, as 
well as via stimulation of antioxidant enzymes [176]. More-
over, N1-acetyl-N2-formyl-5-methoxykynuramine (AMFK), 
which is one of the metabolic products of melatonin, can 
donate two electrons to free radicals and thus scavenge ROS 
[177]. In addition, melatonin is a potent regulator of reduc-
tion and oxidation reactions in cells. For example, melatonin 
and its metabolites can inhibit upregulation and activation of 
COX-2 and iNOS, thus suppresses inflammation and subse-
quent oxidative damage [178, 179]. Since melatonin is a 
natural body antioxidant, its usage has less toxicity as well as 
appropriate penetration in various organs [180]. This makes 
the possibility of radioprotection of different organs with 
melatonin. These abilities allow its classification as a natural 
and photochemical agent for protection against the cytotoxic 
effects of radiation [181, 182]. 
Several in vitro and in vivo studies have investigated the 
radioprotective effects of melatonin. Animal studies were 
conducted for various organs such as lung, heart, kidney, 
liver, gastrointestinal system, skin, testes, lenses, spinal cord 
and others [183-191]. Although the clinical applications for 
possible radioprotection of melatonin have suffered limita-
tions, some have shown promising results. A clinical study 
by Lissoni et al. [192] showed that treatment with melatonin 
(20 mg daily) for patients with glioblastoma undergoing ra-
diotherapy resulted in better survival and minimal side ef-
fects. This study involved 30 patients who received fraction-
ated radiotherapy with a total dose of 60 Gy. Ben et al. [193] 
in phase II, prospective, randomized clinical study evaluated 
the role of a melatonin-containing emulsion on the occur-
rence of radiation-induced dermatitis in patients who under-
went radiotherapy for breast cancer. Their study showed that 
melatonin-containing emulsion caused the reduction of grade 
1/2 dermatitis by 90%. In contrast to these studies, another 
research reported that administering melatonin (20 mg/day) 
for patients with brain metastases has no beneficial effect on 
their survival [90]. Further studies, especially for patients 
with breast and prostate cancer, may have interesting find-
ings. 
16. SECOISOLARICIRESINOL DIGLUCOSIDE (SDG) 
SDG is one of the most abundant dietary lignans such as 
flaxseed, while numerous other herbal agents like blackberry 
and wheat contain a substantial concentration of SDG. Stud-
ies have reported that SDG has potent antioxidant and anti-
inflammatory effects [194, 195]. SDG has the ability to 
scavenge free radicals generated by ionizing radiation, lead-
ing to protection of the genomic contents of cells. This effect 
was seen in both pre and post-irradiation treatments with 
different radiation doses [196, 197]. SDG can modulate 
apoptosis pathways via changes in miRNAs levels involved 
in cell death. Treatment with flaxseed showed a reduction in 
mir34 by 50%, resulting in attenuation of radiation-induced 
apoptosis and senescence [198]. Moreover, it can alleviate 
inflammatory responses through attenuation of NLRP3 in-
flammasome activation [199]. 
Lee et al. showed that administering flaxseed (10% 
(w/w) for 3 weeks before thorax irradiation with a single 
dose of 13.5 Gy can alleviate radiation-induced acute and 
chronic inflammation, as well as fibrosis [200]. Similar re-
sults were obtained from a clinical study. Treatment with 
dietary Flaxseed for patients with non-small cell lung carci-
noma could ameliorate radiation-induced pneumonitis. This 
process was done daily from the start of radiotherapy to 2 
weeks after treatment [201]. 
Treatment with flaxseed has shown a potent mitigatory 
effect for mice lung and heart tissues. Solomidou et al. eval-
uated the mitigatory effect of SDG on different time points 
after thorax irradiation with a single dose of 13.5 Gy. Treat-
ment with SDG (10% (w/w) showed an increase in survival 
of mice more than twice within a period of 4 months after 
exposure. This was associated with decreasing pulmonary 
heart fibrosis as well as inflammation, resulting from sup-
pression of inflammatory and pro-fibrotic cytokines secre-
tion. The mitigatory effect of SDG was more obvious when 
administered 2 weeks after exposure [202, 203]. A similar 
result, although with low survival was observed for treat-
ments 1, 2 or 3 days after exposure [204]. 
17. GINKGO BILOBA 
Ginkgo biloba is one of the oldest species proposed for 
some clinical use due to its strong antioxidant properties. 
Extracts of Ginkgo biloba have been proposed for the im-
provement of some mental disorders such as dementia and 
Alzheimer [205-208]. In 2009, the radioprotective effect of 
Ginkgo biloba was detected in human and mice lymphocytes 
in a study by Shin et al. They treated mice with 500 µg/kg 
before irradiation with 4.5 Gy of gamma rays. Also, they 
observed its radioprotective after a 2-week treatment of hu-
man lymphocytes with 1 to 500 µg/kg. Results showed that 
Ginkgo biloba attenuates radiation-induced apoptosis in a 
dose-dependent manner. Moreover, it could reverse the 
effects of ionizing radiation on the decreased size of mice 
spleen [209]. A study by Okumus et al. showed the protec-
tive effect of Ginkgo biloba on radiation-induced oxidative 
injury in rat’s lens. They used 40 mg/kg/day for 3 days be-
fore irradiation to ten consecutive days after irradiation with 
5 Gy. Afterward, the antioxidant levels of the lenses were 
evaluated. Results indicated that treatment with Ginkgo bi-
loba caused a significant improvement in the total content of 
antioxidant enzymes and non-enzymes such as glutathione 
reductase and glutathione-Stransferases, as well as a reduc-
tion of xanthine oxidase content. These changes were associ-
ated with a reduction of cataract appearance in rat’s lenses 
[210]. A similar study revealed that it can alleviate the 
increased level of oxidative stress and augment the activity 
of SOD and GSH in rat’s lens [211]. Şener et al. showed that 
in addition to the enhancement of antioxidant capacity, 
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Ginkgo biloba has the ability to ameliorate the upregulation 
of TNF-α and Lactate dehydrogenase in rat’s serum and tis-
sues following irradiation [212]. 
18. SELENIUM 
Selenium is a trace element which is required for the 
formation of several selenoproteins with key roles in im-
portant metabolic processes. In the human body, 
selenoenzymes and selenoproteins are considered as vital 
components of the antioxidant enzymes including glutathi-
one peroxidase (GSH-Px) [213]. In addition, selenium has 
the ability to cooperate with other natural antioxidants like 
vitamins C and E for protecting the normal cells against oxi-
dative damage. Seleno-L-methionine and N-acetylcysteine 
(NAC) are two main natural sources of selenium that have 
shown potent antioxidant and radioprotective properties 
[214, 215]. 
Selenium has potent radioprotective and mitigatory prop-
erties in terms of radiation toxicity. Clinical studies of sele-
nium adjuvant for radioprotection have focused on patients 
with brain tumor. A study by Buentzel et al. [216] revealed 
its ability to reduce side effects of radiation therapy on head 
and neck cancer therapy including xerostomia, mucositis and 
dysphagia. They used 1 mg/day for patients undergoing radi-
ochemotherapy and 0.5 mg/day for radiotherapy patients. A 
total of 39 patients were involved. The results of this study 
indicated that treatment with selenium resulted in a signifi-
cant reduction of acute xerostomia and mucositis. In addi-
tion, the incidences of xerostomia and mucositis have no 
difference with results obtained from amifostine. However, 
the efficiency of selenium for ageusia and dysphagia report-
ed was very limited [217]. Another study by Max et al. [218] 
didn't show radioprotection for these side effects after ad-
ministering Seleno-L-methionine (dose of 3600 μg/m2, twice 
daily for 7 days before radiotherapy). Despite protective ef-
fect of selenium, it has not shown any improvement in sur-
vival of patients with glioblastoma multiforme [219]. How-
ever, no study has shown the disadvantages of its effects 
such as reduction in tumor response to radiotherapy [220]. 
The results of mitigatory effects of selenium are very in-
teresting. In-vitro studies revealed that incubating irradiated 
cells with selenium leads to reduced DNA damage and ex-
pression of genes involved in oxidative damage [221, 222]. 
The mitigatory effects were confirmed in in vivo studies as 
well. An animal study by Sieber et al. showed that treatment 
of rats with seleno-L-methionine or sodium selenite after 
exposure to 10 Gy radiation resulted in a reduction of dam-
age to kidney functions. This was followed by treatment with 
100 μg/day of selenium compounds for 21 weeks after irra-
diation [52]. In another follow-up study, these authors 
showed that supplementing with 200 μg of selenium per day 
is more effective in mitigating radiation toxicity on the 
nephrophysiological functions compared to higher or lower 
doses. The results showed a reduction in serum levels of 
blood urea nitrogen (BUN) from 115 mg/dl to lower than 80 
mg/dl as well as ameliorating pathological damages [223]. 
19. TOCOPHEROLS 
The α-tocopherol which is named "vitamin E", is the 
strongest form of tocopherol elements found in varieties of 
foods such as wheat germ, vegetable oils like olive and sun-
flower oils etc. [224]. The α-tocopherol is one of the most 
abundant fat-soluble antioxidants in tissues and plasma with 
a high biological activity [225]. This antioxidant has a hy-
droxyl group, with the ability to donate a hydrogen atom in 
order to reduce free radicals [226]. These properties of α-
tocopherol make it one of the most interesting agents for 
radiation protection and mitigation. 
The radioprotective effects of α-tocopherol have been 
confirmed years ago. It can protect sensitive organs such as 
bone marrow and intestinal against toxic effects of radiation 
[227]. Some studies proposed that α-tocopherol ameliorates 
toxic effects of radiation on bone marrow stem cells through 
stimulation of some cytokines and growth factors such as IL-
6, granulocyte-colony stimulating factor (G-CSF), and cer-
tain chemokines which augment hematological cellular re-
covery [228-232]. These properties of α-tocopherol associat-
ed with potent radical scavenging effect make it a promising 
agent for radiation mitigation as well. Anzai et al. proposed 
gamma-tocopherol-N and N-dimethylglycine ester, which is 
a water-soluble derivative of vitamin E as a potent radiopro-
tector and mitigator. They showed that treatment with this 
derivative can mitigate the detrimental effects of an exposure 
to 7.5 Gy x-rays. Their results indicated that gamma-
tocopherol-N,N-dimethylglycine ester stimulates the recov-
ery of bone marrow cells following exposure [233]. 
20. ASCORBIC ACID 
Ascorbic acid (Vitamin C) is a potent antioxidant that ef-
fectively scavenges superoxide and ROS. Moreover, it has 
an important role in the regulation of intracellular redox state 
and neutralizes endogenous radical species by suppressing 
excess superoxide generation by mitochondrial metabolism 
and ROS/NO producing enzymes such as xanthine oxidase, 
NADPH oxidase, and nitric oxide synthase [234, 235]. The 
potent antioxidant properties of ascorbic acid can reduce 
oxidative damage resulting from exposure to radiation. On 
the other hand, its redox modulatory effect makes it a poten-
tial radiation mitigator [236]. 
Ascorbic acid has shown the ability to reduce radiation 
toxicity in various organs such as testes, intestine, bone mar-
row, skin and others [237-240]. The administered dose of 
ascorbic acid in these studies was different from 10 mg/kg to 
300 mg/kg. However, it has no reported toxicity for any of 
these drug doses. Sato et al. showed that treatment of irradi-
ated mice with a single dose of 3 g/kg ascorbic acid can mit-
igate lethal effect and other hematological damages after 
exposure to a 7 to 8 Gy gamma rays. However, higher doses 
of ascorbic acid may lead to cytotoxicity. They showed sig-
nificant improvements in survival following treatment with 
ascorbic acid 24 hours after exposure, while 36 hours after 
irradiation did not show mitigatory effect. Furthermore, their 
results revealed that its post-irradiation treatment suppresses 
inflammatory cytokines such as IL-1 and IL-6, as well as 
radiation-induced apoptosis [241]. 
21. BETA-CAROTENE 
Beta-carotene (C40H56) is the most abundant form of vit-
amin A found naturally in fruits and vegetables. It is a 
hydrogen-rich compound, with considerable interest due to 
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its antioxidant properties [242]. Epidemiological studies 
have reported that dietary intake of Beta-carotene is associ-
ated with a reduced risk of several diseases such as cancer 
[243, 244]. Beta-carotene acts by suppressing the oxidative 
action of ROS and singlet oxygen. In addition, Beta-carotene 
suppresses redox based inflammation activation via suppres-
sion of ROS producing enzymes such as iNOS and COX-2, 
and downregulates inflammatory mediators such as NF-κB 
[245]. However, in high dose supplements, it may act as a 
pro-oxidant and reduces antioxidants in the cell, leading to 
oxidative DNA damage [246, 247]. Treatment with Beta-
carotene has been tested for clinical radiotherapy applica-
tions as well as Chernobyl survivors. These studies have 
found interesting results without significant toxicity or other 
side effects. 
In 1988, a study by Mills [248] showed that administer-
ing beta-carotene to radiotherapy and chemotherapy patients 
result in a decrease of oral mucositis. Patients included 20 
individuals with advanced squamous carcinoma of the 
mouth. Each of them received 60 Gy of 60Co gamma rays in 
30 fractions. In addition, patients received chemotherapy 
drugs such as bleomycin, vincristine and methotrexate. On 
the other hand, a randomized clinical trial study by Margalit 
et al. showed that treatment with beta-carotene for prostate 
cancer patients who have undergone radiotherapy had no 
impact on the therapeutic effect of radiation as well as the 
treatment outcome. However, these results cannot be extrap-
olated to all cancers [92]. 
In vivo studies have revealed that treatment with beta-
carotene is effective in amelioration of radiation toxicities in 
different tissues such as liver, thyroid gland, gastrointestinal 
system, bone marrow and blood [249-253]. However, for 
parotid glands, no radioprotective effect was observed [254]. 
These studies indicated that beta-carotene protects cells 
against ionizing radiation via scavenging of ROS and stimu-
lation of SOD and catalase. Also, it is able to reduce apopto-
sis in radiosensitive cells like human T cells [255]. Although 
beta-carotene may reduce oxidative damage via regulation of 
redox based enzymes, further studies are needed to confirm 
the effect of beta-carotene on ROS producing enzymes such 
as NADPH oxidase, COX-2, iNOS, lipoxygenases, and oth-
ers. 
Ben-Amotz and colleagues evaluated the effects of 
treatment with beta-carotene on serum blood oxidative stress 
markers in children who had exposed to radiation for a long 
time following the Chernobyl accident. They evaluated 709 
children comprising 385 girls and 324 boys from the con-
taminated areas. Primary results showed an increased level 
of oxidation markers in serum blood of children, especially 
for girls. Furthermore, supplementing with a 40 mg natural 
mixture including beta-carotene for 3 months resulted in a 
remarkable reduction of oxidation markers [256]. This study 
is a good example of the mitigatory effects of beta-carotene 
in reducing the risk of carcinogenesis among irradiated peo-
ple in a radiation disaster. 
22. COENZYME Q10 
Coenzyme Q10 (CoQ10) or ubiquinone is a fat-soluble 
compound that is synthesized in most mammalian cells. It 
has been identified as an important co-factor in numerous 
biological processes [257]. The most crucial role of this co-
factor is in mitochondria, which acts as an electron carrier in 
the respiratory chain [258]. The reduced form of CoQ10 has 
potent antioxidant effects in cellular organelles especially 
mitochondria and lipid membranes [259]. In addition, Q10 
has the ability to stimulate expression of antioxidant en-
zymes including SOD and catalase [260]. Furthermore, it can 
complement the antioxidant activity of alpha-tocopherol 
[261]. 
Q10 showed a radioprotective role in some organs. Ki et 
al. [262] showed that daily administering of 10 mg/kg CoQ10 
to rats for 24 weeks after irradiating the abdomen resulted in 
a significant improvement in kidney function. In addition, 
Q10 reduced glomerulosclerosis and tubulointerstitial fibro-
sis caused by radiation. Treatment with a similar dose of Q10 
has shown the ability to ameliorate oxidative damage in rats' 
brain [263]. In animal studies, administering Q10 in higher 
doses like 100 mg/kg have shown protection against other 
side effects of ionizing radiation such as fatigue [264]. Alt-
hough human studies are very limited, it has shown amelio-
ration of pneumonitis in patients with lung cancer. Treatment 
was continued for 6 months after radiotherapy [265]. 
23. α-LIPOIC ACID (ALA) 
ALA (C8H14O2S2) was discovered in 1930 while its anti-
oxidant properties were observed in 1980. It is a natural co-
enzyme found in mitochondrial complexes. It catalyzes the 
oxidative decarboxylation of α-keto acids such as pyruvate 
and branched-chain α-keto acid [266]. Various experiments 
have revealed the ability of ALA to combat oxidative dam-
age via quenching a variety of intracellular free radicals 
[267]. In addition, ALA is involved in the recycling of some 
other natural cellular ROS scavengers such as ascorbic acid, 
α-tocopherol, and GSH [268]. These properties make ALA a 
potent antioxidant for preventing pathologies involving oxi-
dative damage. 
In an in vitro study, ALA has shown amelioration of oxi-
dative damage induced by NO and ROS, reduces inflamma-
tory markers, and also restores antioxidant enzymes such as 
SOD and GSH [269]. Kang et al. [270] investigated the radi-
oprotective effect of ALA on the small intestine of mice. The 
mice were treated with 100 mg/kg of ALA for 3 days before 
irradiation. Results showed that its administration had no 
effect on food intake as well as the small intestinal villus. 
Treatment before irradiation led to a reversal of reducing 
villus numbers and height. Moreover, pre-treatment with 
ALA caused decreased inflammatory markers, apoptosis and 
oxidative damage, while restoring the GSH content of intes-
tinal cells. It has the ability to ameliorate radiation-induced 
fibrosis. Ryu et al. in a mice model showed that p65 acetyla-
tion is necessary for the activation of pro-fibrotic genes after 
exposure to radiation. ALA inhibition of Ac-p65 and p300 
can reduce p65 acetylation and histone acetyltransferase ac-
tivity during fibrosis, resulting in down regulation of fibrotic 
mediators such as MMP-2, PAI-1, and also NF-κB transcrip-
tion. As NF-κB has a role in enhancing MMP-2 and PAI-1 
via binding to their promoters, suppressing NF-κB by ALA 
has a central role in ameliorating radiation-induced fibrosis 
[271]. 
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It has been shown that ALA has the ability for protection 
against high-energy particle radiation in mice brain. Expo-
sure to HZE is very important in deep space missions as well 
as in hadron therapy. Treatment of mice with 200 mg/kg 
ALA 30 minutes before irradiation (1.5 Gy) showed attenu-
ated oxidative damage and apoptosis in the cerebellum as 
well as memory dysfunction [272]. ALA (200 mg/kg) has 
shown a reversal in decreased sulfhydryl content of cerebel-
lum and plasma after localized brain exposure to ionizing 
radiation (6 Gy X-rays) [273]. In addition, it has a mitigatory 
effect among children that has been exposed to the Cherno-
byl disaster. Treatment with ALA for 28 days among inhab-
itant children in the contaminated area resulted in a reduction 
of oxidative stress [274] (Table 1). 
24. COMBINATION FORM OF ANTIOXIDANTS 
Some researchers have proposed that using a combina-
tion of two or more different antioxidants may be more ef-
fective in reducing radiation toxicity. So far, various combi-
nations have been tested for this aim [278, 279]. A combina-
tion of α-tocopherol acetate and ascorbic acid, likewise a 
combination of some other antioxidants like selenium and 
Q10 with other antioxidants have been studied in several 
experiments [280, 281]. 
A combination of α-tocopherol acetate and ascorbic acid 
may have some synergic effects on radiation toxicity as well 
as reduction of radioactive particles that may be absorbed 
after a radiation accident [282]. Administering this combina-
tion (10mg/kg each) before and after irradiation of rats 
showed effective treatment when applied before exposure. It 
is interesting to note that individual treatment with either α-
tocopherol acetate or ascorbic acid before or after irradiation 
had no remarkable effect on reduction of chromosome aber-
rations in the plasma and bone marrow [283]. This effect was 
also observed in the plasma level of DNA fragments. Treat-
ment with single vitamin E (10mg/kg) or C (20mg/kg) did 
not show any radioprotection, while their combination could 
protect cells from radiation-induced chromosomal aberra-
tions [284]. 
Some studies have shown promising results for radiopro-
tection and mitigation using a combination of natural antiox-
idants such as Selenium-L-Methionine, N-acetyl cysteine, a-
lipoic acid, Q10, and others. Guan et al. [285, 286] showed 
that a combination of these agents associated with ascorbic 
acid and alpha-tocopherol can reverse the reduction of serum 
levels of total antioxidants after exposure of rats to high LET 
radiation. Administering a combination of these agents 
showed a reversal in the reduction of total white blood cells 
and neutrophil counts, as well as inhibiting apoptotic genes 
in bone marrow cells of mice after exposure to gamma rays 
[287]. These results have been investigated for total body 
exposure to proton radiation as well [288]. Brown et al. 
showed that a combination of Selenium-L-Methionine, N-
acetyl cysteine, a-lipoic acid, Q10, sodium ascorbate can 
mitigate total body exposure to 8 Gy gamma rays. They 
showed that administering a diet comprising these agents 24 
hours after irradiation of mice was more effective in compar-
ison to sooner or later times. Furthermore, their results re-
vealed the ability of this combination to protect bone marrow 
cells against chronic oxidative damage, and also attenuate 
the upregulation of genes involved in the apoptosis pathway 
[289]. 
A combination of α-tocopherol and ALA also showed 
mitigatory effect. A study on children exposed to Chernobyl 
contaminated area showed that a combination of these anti-
oxidants is more effective in comparison to each of the indi-
vidual agents [274]. In addition to natural antioxidants, the 
combination forms of flavonoids have been investigated for 
radioprotection too. Two studies by Gupta et al. [290] re-
vealed that a combination of podophyllotoxin and rutin can 
protect mice against ionizing radiation. They showed that 
this compound stimulates nuclear factor erythroid-derived 
like-2 factor (Nrf-2) that act as an activator of GSH and other 
antioxidant enzymes. Also, it can induce anti-apoptotic genes 
(Bcl-2 and Bcl-xL) in bone marrow cells, suppress inflam-
matory mediators and cytokines in gastrointestinal. Adminis-
tering a diet containing several types of antioxidants can 
significantly improve the survival rate after mice irradiation. 
Epperly et al. showed that an antioxidant diet administered 
with mnSOD can reduce a 30-day mortality from 45% to 
17.5% [291]. 
CONCLUSION 
After approval of amifostine as radioprotectors, several 
experiments have been conducted to identify novel radiopro-
tectors with less toxicity. Moreover, amifostine offers lim-
ited protection against radiation to some organs. Radiopro-
tection with herbal and phytochemical agents has been of 
high interest in the recent decade. Although curcumin is the 
most famous herbal agent which has been studied for its anti-
inflammatory and antioxidant effects, several studies have 
shown promising results for some other agents. Other herbal 
agents such as hesperidin, melatonin, quercetin, and sesamol 
have shown interesting radioprotective results, while in re-
cent years some studies proposed resveratrol as a new radio-
protector. Although herbal agents have been studied for radi-
oprotection, using these agents for mitigation may show in-
teresting results. A potent effect of herbal radioprotectors is a 
result of their anti-inflammatory effects. The aforementioned 
agents have shown the ability to attenuate inflammation me-
diators such as NF-κB and SMAD, leading to amelioration 
of inflammatory cells recruitment and reduced level of in-
flammatory cytokines. The direct antioxidative effects of 
herbal agents or stimulation of antioxidant enzymes also 
contribute to their radioprotective effects. Although these 
effects are different for various agents. For example, sesamol 
has a potent direct antioxidant, curcumin inhibit inflammato-
ry mediators, and resveratrol scavenges free radicals via 
stimulation of antioxidant enzymes, while it can't scavenge 
ROS and NO directly. 
Natural antioxidants have shown some limited radiopro-
tection, while a combination of two or more different antiox-
idants may have better radioprotective effects in comparison 
to a single agent. This is an area of high interest in the devel-
opment of radiation mitigators for the safety of people ex-
posed to nuclear or radiological disasters. A combination of 
antioxidants or radioprotectors with different radioprotective 
mechanisms can offer protection in a synergic manner. For 
example, a combination of ascorbic acid as a hydrophilic 
agent with alpha-tocopherol as a lipophilic agent can protect 
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Table 1. Different herbal and natural antioxidants for radioprotection.  
Agent  Structure  
In-vitro/in-vivo 
route 
Dose range 
Dose reduction 
factor (DRF)  
Mechanisms of action Ref  
Curcumin C21H20O6 
In-vitro/in-vivo, 
Human 
Up to 8 gm/day 
for human 
1.15 
Targeting of NF-κB and 
inflammatory cytokines, 
scavenging of ROS and NO 
[99, 101] 
Hesperidin  C28H34O15 Mice, Rat 
No toxicity up to 
100 mg/kg 
- 
Preventing of immune cell 
recruitment, stimulation anti-
oxidant enzymes,  
[117] 
Resveratrol  C14H12O3 Mice 
No toxicity up to 
100 mg/kg 
40% increase in 
survival 
Suppression of NOX4, simu-
lation of Sirt-1, stimulation of 
antioxidant enzymes 
[131] 
Quercetin  C15H10O7 Mice  
No toxicity up to 
100 mg/kg 
1.11 
Inhibition of NF-κB and 
MAPKs, stimulation of anti-
oxidant enzymes, scavenging 
of ROS 
[143, 144, 275] 
Ocimum Sanc-
tum 
- Mice 200 mg/kg - 
Scavenging of ROS, stimula-
tion of antioxidant enzymes 
[150] 
Rutin  C27H30O16 In vitro, Mice  50 mg/kg 1.15 
Scavenging of ROS, stimula-
tion of antioxidant enzymes 
[160, 275] 
Caffeic Acid C9H8O4 Mice 30 mg/kg 1.1-1.2 
Scavenging of ROS, recycle 
of GSH, suppression of in-
flammatory cytokines 
[172] 
Sesamol  C7H6O3 Mice  
No toxicity up to 
100 mg/kg 
70% survival in 
50mg/kg 
Scavenging of ROS, activa-
tion of GSH and catalase 
[167] 
Melatonin  C13H16N2O2 
In-vitro/in-vivo, 
Human 
No toxicity up to 
100 mg/kg. for 
clinical studies 
has tested to 
20mg/kg 
1.53 
Scavenging of ROS and NO, 
stimulation of antioxidant 
enzymes, Suppression of 
Redox system activity, inhibi-
tion of inflammatory respons-
es  
[192, 276] 
SDG C32H46O16 
In-vitro/in-vivo, 
Human 
No toxicity up to 
3g/kg. for clinical 
studies has tested 
to 
- 
Inhibition of NLRP3 inflam-
masome,  
[199] 
Ginkgo biloba 
Containing 
several chemi-
cal composi-
tions 
In-vitro/in-vivo 
1 µg/kg to 
50mg/kg 
- 
Stimulation of antioxidant 
enzymes, suppression of 
TNF-α 
[212] 
Selenium  Se Human, Rat 1 mg per day  
80% survival 
for selenium-L-
Methionine 
Scavenging of ROS, activa-
tion of natural antioxidants 
like vitamin C and E, and also 
antioxidant enzymes 
[217, 277] 
α-tocopherol C29H50O2 Mice  100 mg/kg - 
Scavenging of ROS, stimula-
tion of growth factors such as 
IL-6 and G-CSF 
[233] 
Ascorbic Acid C6H8O6 Mice 
No toxicity up to 
3 gr/kg 
20% survival 
for post 
exposure treat-
ment and 80% 
survival for pre-
Scavenging of ROS, inhibi-
tion of Redox system 
[241] 
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Agent  Structure  
In-vitro/in-vivo 
route 
Dose range 
Dose reduction 
factor (DRF)  
Mechanisms of action Ref  
treatment (8Gy 
x-rays) 
Beta-carotene  C40H56 
In-vitro/in-vivo, 
Human 
40 mg daily for 
human 
1.26 
Inhibition of redox-based 
enzymes such as iNOS and 
COX-2, downregulating NF-
κB, Stimulation of SOD and 
CAT 
[255] 
Q10 C59H90O4 Rats, human 
No toxicity up to 
100 mg/kg 
- Stimulation of SOD and CAT [264] 
Α-lipoic acid C8H14O2S2 Mice  
No toxicity up to 
100 mg/kg 
1.26 
Inhibition of NF-κB, Scav-
enging of ROS, restore of 
GSH, recycling of ascorbic 
acid and α-tocopherol 
[270, 271] 
 
both the fat and hydrophilic environments within the cells. 
This result was investigated for a combination of ALA with 
alpha-tocopherol. ALA can recycle ascorbic acid and alpha-
tocopherol, as well as stimulate GSH. Hence, it is predicted 
that a combination of ALA with these agents may have syn-
ergic effects on radioprotection. The combination of differ-
ent agents for radioprotection and mitigation have attracted 
more attention in recent years. Therefore, immunomodulato-
ry agents such as anti-inflammatory, anti-apoptosis, and re-
dox modulatory compounds are most promising for the de-
velopment of radiation mitigators. 
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